Endometriosis and ovarian cancer: A review

Gynecological Endocrinology

Volumn 26, Issue 3, 2010, Pages 213-219

  Vlahos, Nikos F ^a,b   Kalampokas, Theodoros ^b   Fotiou, Stylianos ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cancer; Endometriosis; Infertility; K ras; Ovary; PTEN

Indexed keywords

ALPHA CATENIN; AROMATASE INHIBITOR; BETA CATENIN; DIOXIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; GELATINASE A; GELATINASE B; GESTAGEN; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; P CADHERIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROSTAGLANDIN; PROSTAGLANDIN E2; PROTEIN P53; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BODY MASS; CANCER INVASION; CHRONIC INFLAMMATION; CLEAR CELL CARCINOMA; DISEASE PREDISPOSITION; DOWN REGULATION; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; ESTROGEN THERAPY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC STABILITY; GENOMIC INSTABILITY; HORMONE SUBSTITUTION; HUMAN; LITERATURE; MEDLINE; MENSTRUATION; METASTASIS; METHODOLOGY; MOLECULAR BIOLOGY; ONCOGENE K RAS; OVARY CANCER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UTERINE TUBE LIGATION;

EID: 77249095032     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590903184050     Document Type: Article

References (55)

1. Mahmood TA. The impact of previous danazol treatment on circulating hormone levels, follicular development and oocyte maturity in minimal-mild endometriosis. Eur J Obstet Gynecol Reprod Biol 1991;41:207-214.
2. Lapp T. ACOG issues recommendations for the management of endometriosis. American College of Obstetricians and Gynecologists. Am Fam Physician 2000;62:1431-1434.
3. Sampson J. Endometrial carcinoma of the ovary arising in endometrial tissue in that organ. Arch Surg 1925;10:72.
4. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 1997;176:572-579.
5. Melin A, Sparen P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod 2006;21:1237-1242.
6. Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF, Jr., Nikrui N, Goff BA. Histologic transformation of benign endometriosis to early epithelial ovarian cancer.Gynecol Oncol 1996;60:238-244.
7. Vercellini P, Scarfone G, Bolis G, Stellato G, Carinelli S, Crosignani PG. Site of origin of epithelial ovarian cancer: the endometriosis connection. BJOG 2000;107:1155-1157.
8. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 2003;189:280-294.
9. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M, Schlesselman JJ. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11:111-117.
10. Obata K, Hoshiai H. Common genetic changes between endometriosis and ovarian cancer. Gynecol Obstet Invest 2000;50(Suppl 1):39-43.
11. Druckmann R, Rohr UD. IGF-1 in gynaecology and obstetrics: update 2002. Maturitas 2002;41(Suppl 1):S65-S83.
12. Kobayashi H, Sumimoto K, Kitanaka T, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaquchi R, Kanayama S, Shigetomi H, et al. Ovarian endometrioma - risks factors of ovarian cancer development. Eur J Obstet Gynecol Reprod Biol 2008;138:187-193.
13. Melin A, Sparen P, Bergqvist A. The risk of cancer and the role of parity among women with endometriosis. Hum Reprod 2007;22:3021-3026.
14. Brinton LA, Sakoda LC, Sherman ME, Frederiksen K, Kjaer SK, Graubard BI, Olsen JH, Mellemkiaer L. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev 2005;14: 2929-2935.
15. Borgfeldt C, Andolf E. Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 2004;83:395-400.
16. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004;82:405-414.
17. Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer 2009;124:1409-1415.
18. Nagle CM, Olsen CM, Webb PM, Jordan SJ, Whiteman DC, Green AC. Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer 2008;44: 2477-2484.
19. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 2004;191:733-740.
20. Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med 2001;345:266-275.
21. Vercellini P, Parazzini F, Bolis G, Carinelli S, Dindelli M, Vendola N, Luchini L, Crosignani PG. Endometriosis and ovarian cancer. Am J Obstet Gynecol 1993;169:181-182.
22. Ogawa S, Kaku T, Amada S, Kobayashi H, Hirakawa T, Ariyoshi K, Kamura T, Nakano H. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol 2000;77:298-304.
23. Van Gorp T, Amant F, Neven P, Vergote I, Moerman P. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res 2004;18:349-371.
24. Miracle-McMahill HL, Calle EE, Kosinski AS, Rodriguez C, Wingo PA, Thun MJ, Heath CW Jr. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am J Epidemiol 1997;145:349-357.
25. Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev 1996;5:933-935.
26. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, Hennekens SH, Speizer FE. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993;270:2813-2818. (Pubitemid 23361643)
27. Hempling RE, Wong C, Piver MS, Natarajan N, Mettlin CJ. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 1997;89:1012-1016. (Pubitemid 27220471)
28. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497-504. (Pubitemid 34411288)
29. Zanetta GM,Webb MJ, Li H, Keeney GL. Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. Gynecol Oncol 2000;79:18-22.
30. Bulun SE, Zeitoun K, Takayama K, Noble L, Michael D, Simpson E, Johns A, Putman M, Sasano H. Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer 1999;6:293-301.
31. Bulun SE, Zeitoun KM, Takayama K, Sasano H. Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update 2000;6:413-418. (Pubitemid 30763279)
32. Osuga Y. Novel therapeutic strategies for endometriosis: a pathophysiological perspective. Gynecol Obstet Invest 2008; 66(Suppl 1):3-9.
33. Ness RB, Modugno F. Endometriosis as a model for inflammation-hormone interactions in ovarian and breast cancers. Eur J Cancer 2006;42:691-703.
34. Nezhat F, Datta MS, Hanson V, Pejovic T, Nezhat C, Nezhat C. The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril 2008;90:1559-1570.
35. Bulun SE, Simpson ER. Aromatase expression in women's cancers. Adv Exp Med Biol 2008;630:112-132.
36. Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab 2000;85:2897-2902.
37. Matsuzaki S, Canis M, Murakami T, Dechelotte P, Bruhat MA, Okamura K. Expression of the cyclindependent kinase inhibitor p27Kip1 in eutopic endometrium and peritoneal endometriosis. Fertil Steril 2001;75:956-960.
38. Seeger H, Wallwiener D, Kraemer E, Mueck AO. Estradiol metabolites are potent mitogenic substances for human ovarian cancer cells. Eur J Gynaecol Oncol 2005;26:383-385.
39. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 2005;12:851-866.
40. Arvanitis DA, Koumantakis GE, Goumenou AG, Matalliotakis IM, Koumantakis EE, Spandidos DA. CYP1A1, CYP19, and GSTM1 polymorphisms increase the risk of endometriosis. Fertil Steril 2003;79(Suppl 1):702-709.
41. Birnbaum LS, Cummings AM. Dioxins and endometriosis: a plausible hypothesis. EnvironHealth Perspect 2002;110:15-21.
42. Eskenazi B, Mocarelli P, Warner M, Samuels S, Vercellini P, Olive D, Needham LL, Patterson DG Jr, Brambilla P, Gavoni N, et al. Serum dioxin concentrations and endometriosis: a cohort study in Seveso, Italy. Environ Health Perspect 2002;110:629-634. (Pubitemid 34906286)
43. Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril 2001;75:1-10.
44. Meresman GF, Vighi S, Buquet RA, Contreras-Ortiz O, Tesone M, Rumi LS. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril 2000;74:760-766.
45. Johnson MC, Torres M, Alves A, Bacallao K, Fuentes A, Vega M, Boric MA. Augmented cell survival in eutopic endometrium from women with endometriosis: expression of c-myc, TGF-beta1 and bax genes. Reprod Biol Endocrinol 2005;3:45.
46. Varma R, Rollason T, Gupta JK, Maher ER. Endometriosis and the neoplastic process. Reproduction 2004;127:293-304.
47. Obata K, Hoshiai H. Genetic analysis of endometriosis and ovarian cancer. Nippon Rinsho 2001;59(Suppl 1):217-220.
48. Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000;60:7052-7056.
49. Martini M, Ciccarone M, Garganese G, Maggiore C, Evangelista A, Rahimi S, Vittori G, Larocca LM. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer 2002;102:398-406.
50. Otsuka J, Okuda T, Sekizawa A, Amemiya S, Saito H, Okai T, Kushima M, Tachikawa, T. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma. Med Electron Microsc 2004;37:188-192.
51. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005;11:63-70.
52. Prefumo F, Venturini PL, Fulcheri E. Analysis of p53 and cerbB- 2 expression in ovarian endometrioid carcinomas arising in endometriosis. Int J Gynecol Pathol 2003;22:83-88.
53. Sainz de la Cuesta R, Izquierdo M, Canamero M, Granizzo JJ, Manzarbeitia F. Increased prevalence of p53 overexpression from typical endometriosis to atypical endometriosis and ovarian cancer associated with endometriosis. Eur J Obstet Gynecol Reprod Biol 2004;113:87-3.
54. Mizumoto H, Saito T, Ashihara K, Nishimura M, Takehara M, Tanaka R, Ito E, Kudo R. Expression of matrix metalloproteinases in ovarian endometriomas: immunohistochemical study and enzyme immunoassay. Life Sci 2002;71: 259-273.
55. Ueda M, Yamashita Y, Takehara M, Terai Y, Kumagai K, Ueki K, Kanda K, Hung YC, Ueki M. Gene expression of adhesion molecules and matrix metalloproteinases in endometriosis. Gynecol Endocrinol 2002;16:391-402.